Research programme: CETP inhibitors - Eli Lilly
Latest Information Update: 24 Mar 2009
At a glance
- Originator Eli Lilly
- Class Small molecules
- Mechanism of Action Cholesterol ester transfer protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Atherosclerosis
Most Recent Events
- 24 Mar 2009 Preclinical development is ongoing in USA
- 20 Apr 2007 Preclinical trials in Atherosclerosis in USA (unspecified route)